Authors

Yi Lin, MD, PhD

Latest:

Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Yazan Madanat, MD, UT Southwestern Medical Center

Latest:

MDS Treatment Selection: Impact of QoL

Drs Madanat and Sekeres comment on the importance of quality of life and patient perspective in the selection of MDS treatment.

Jose Maria Mazarico Gallego, MD

Latest:

Dr. Gallego on the Impact of COVID-19 on Cancer Care in Spain

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Neil Vasan, MD, PhD

Latest:

Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Ignace B. Vergote, MD, PhD

Latest:

Dr. Vergote on the Need to Develop Novel Therapies in Endometrial Cancer

Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.

Rondell P. Graham, MBBS

Erin Roesch, MD

Latest:

A Dynamic Treatment Landscape Emerges for Early-Stage TNBC

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

John Nakayama, MD

Latest:

Dr. Nakayama on Using Precision Medicine With Mirvetuximab Soravtansine in Ovarian Cancer

John Nakayama, MD, discusses the potential utility of precision medicine with mirvetuximab soravtansine in ovarian cancer.

Alison Schram, MD

Latest:

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Patrick Boland, MD

Latest:

Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Upal Basu Roy, PhD, MPH

Latest:

Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Thomas Cluzeau, MD, PhD

Latest:

Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AML

Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Anne P. O’Dea, MD

Latest:

SABCS 2021: Updates in Metastatic Breast Cancer

Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.

Allen Mo, MD, PhD

Latest:

28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Henry S. Park, MD, MPH

Latest:

Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

Deepu Madduri, MD, Mount Sinai Hospital

Latest:

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center

Latest:

Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

David O’Malley, MD

Latest:

Sequencing Therapy for MSI-High and MMR-Proficient Endometrial Carcinomas

A discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.

Larry Hanover

Latest:

Clinical Trial Diversity Efforts Gain Steam

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.

Caroline Nebhan, MD, PhD

Latest:

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.